Cargando…

Association of Immune Factors with Drug-Resistant Tuberculosis: A Case-Control Study

BACKGROUND: Presently, studies of factors associated with drug-resistant tuberculosis (TB) focus on patients’ socio-demographic characteristics and living habits, to the exclusion of biochemical indicators, especially immune factors. This study was carried out to determine whether immune factors are...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, En-Tao, Xia, Dan, Li, Ben-He, Ma, Jun, Dong, Yuan-Yuan, Ding, Shu-Shu, Chen, Bai-Feng, Wen, Yu-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691569/
https://www.ncbi.nlm.nih.gov/pubmed/29118314
http://dx.doi.org/10.12659/MSM.904309
Descripción
Sumario:BACKGROUND: Presently, studies of factors associated with drug-resistant tuberculosis (TB) focus on patients’ socio-demographic characteristics and living habits, to the exclusion of biochemical indicators, especially immune factors. This study was carried out to determine whether immune factors are associated with drug-resistant TB. MATERIAL/METHODS: A total of 227 drug-resistant pulmonary TB patients and 225 drug-susceptible pulmonary TB patients were enrolled in this study. Information on socio-demographic characteristics and biochemical indicators were obtained through their clinical records. Non-conditional logistic regression was used to analyze the association of these indicators with drug-resistant TB. RESULTS: There were significant differences in re-treatment, marital status, alanine aminotransferase (ALT), blood uric acid (BUA), carcino-embryonic antigen (CEA), T-spot, and CD3 and CD4 counts between the 2 groups. In multivariable analysis, re-treatment [Odds Ratio (OR)=5.290, 95% Confidence Interval [CI]=2.652–10.551); CD3 (OR=1.034, 95% CI=1.001–1.068); CD4 (OR=1.035, 95% CI =1.001–1.070) and IgM (OR=1.845, 95% CI=1.153–2.952) were associated with drug-resistant TB. CONCLUSIONS: These results suggest the need for greater attention to re-treatment cases and immune function when treating drug-resistant TB.